CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities:
Net income (loss)	$ 1,513	$ (2,893)
Adjustments to reconcile net income (loss) to net cash provided by operating activities, net of acquisitions:
Depreciation and amortization	4,087	2,747
Employee stock compensation expense	1,040	380
Changes in deferred taxes	(4,867)
Provision for doubtful accounts	50	(131)
Other non-cash operating activities	7	3
Financing lease interest expense	183	200
Changes in operating assets and liabilities:
Accounts receivable	(4,010)	(701)
Inventories	(277)	(395)
Income tax accruals		154
Accounts payable	1,306	(2,040)
Accrued expenses	1,594	327
Customer advances	7,451	4,063
Other asset and liabilities, net	(28)	(128)
Net cash provided by operating activities	8,049	1,586
Investing activities:
Capital expenditures	(8,358)	(5,094)
Proceeds from sale of equipment	2
Cash paid in acquisitions	(40,698)	(4,000)
Net cash used in investing activities	(49,054)	(9,094)
Financing activities:
Payments on finance lease liability	(277)	(330)
Payments of long-term borrowings	(2,620)	(1,157)
Payments of debt issuance costs	(409)	(111)
Payments on revolving line of credit		(25,326)
Borrowings on revolving line of credit		24,263
Borrowings on construction loans		1,286
Borrowings on capex lines of credit	1,318	2,423
Borrowings on long-term loan	17,087	8,777
Proceeds from exercise of stock options	188	25
Proceeds from issuance of common stock, net	48,972
Net cash provided by financing activities	64,259	9,850
Net increase in cash and cash equivalents	23,254	2,342
Cash, cash equivalents, and restricted cash at beginning of period	1,406	606
Cash, cash equivalents, and restricted cash at end of period	24,660	2,948
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 832	771
Preclinical Research Services acquisition:
Assets acquired		6,442
Liabilities assumed		(1,378)
Common shares issued		(1,133)
Cash paid		$ 3,931